Benfotiamine

Summary

Benfotiamine (CHEMBL4303665) is a phase-3 clinical-stage small molecule (ATC A11DA03); indicated across 4 conditions including diabetic neuropathy and alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A11DA03
• Indications: 4 conditions
• Clinical trials: 10
• Chemistry: 466.4 Da · C19H23N4O6PS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4303665
Name	Benfotiamine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3032771
ATC	A11DA03
Molecular formula	C19H23N4O6PS
Molecular weight	466.4
InChIKey	BTNNPSLJPBRMLZ-LGMDPLHJSA-N

SMILES: CC1=NC=C(C(=N1)N)CN(C=O)/C(=C(/CCOP(=O)(O)O)\SC(=O)C2=CC=CC=C2)/C

IUPAC name: S-[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl] benzenecarbothioate

Also known as: 8088 C.B, 8088 C.B., 8088CB, Benfothiamine, Benfotiamina, Benfotiamine, Benphothiamine, Benzoylthiamine monophosphate, Benzoylthiamine o-monophosphate, Benzoylthiaminmonophosphat, Biotamin, NSC-758241

Patent coverage: 801 distinct patent families (2,501 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 2,357 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, 3’,5’-cyclic-AMP phosphodiesterase 4D, Cytochrome P450 3A4, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	5.5	Potency	3162	nM	CHEMBL_ACT_4014614
PDE4D	5.31	AC50	4900	nM	CHEMBL_ACT_25185075

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetic neuropathy	3	MONDO:0006626	EFO:1000783
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
type 2 diabetes mellitus	2	MONDO:0005148	MONDO:0005148
type 1 diabetes mellitus	1	MONDO:0005147	MONDO:0005147

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE4	4
PHASE3	2
Not specified	2
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00437008	PHASE4	COMPLETED	Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes
NCT00446810	PHASE4	UNKNOWN	Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus
NCT00565318	PHASE4	COMPLETED	Benfotiamine in Diabetic Nephropathy
NCT00680121	PHASE4	COMPLETED	High Dose Vitamin B1 to Reduce Abusive Alcohol Use
NCT00785460	PHASE3	COMPLETED	Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers
NCT01868191	PHASE3	UNKNOWN	Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)
NCT00117026	PHASE1/PHASE2	COMPLETED	Effects of Vitamin B1 in Type 1 Diabetic Patients
NCT02292238	PHASE2	COMPLETED	Benfotiamine in Alzheimer’s Disease: A Pilot Study
NCT00703989	Not specified	COMPLETED	Reactive Oxygen Species in the Pathogenesis of Diabetic Complications
NCT02772926	Not specified	COMPLETED	Benfotiamine Effect on Advanced Glycation End Products(AGEs) and Soluble Receptor for AGEs(sRAGE) in Diabetes Mellitus.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).